Schjesvold F, Voorhees P, Dimopoulos M, Cohen Y, Hungria V, Sandhu I, Lindsay J, Baker R, Suzuki K, Kosugi H, Levin M-D, Beksac M, Stockerl-Goldstein K, Magen H, Oriol A, Mikala G, Garate G, Theunissen K, Spicka I, Mylin A, Hallam S, Bringhen S, Uttervall K, Pula B, Khan A, Medvedova E, Ye J, Cowan A, Moreau P, Mateos M-V, Goldschmidt H, Vieyra D, Raval A, Sha L, Li L, Rousseau E, Dennis R, Carson R, Rajkumar S. B09 | DARATUMUMAB MONOTHERAPY VS. ACTIVE MONITORING IN PATIENTS WITH HIGH-RISK SMOLDERING MULTIPLE MYELOMA: "AQUILA" OUTCOMES BASED ON MAYO 2018/IMWG 2020 RISK STRATIFICATION, IMWG 2020 PLUS CYTOGENETIC CRITERIA, AND AGE. haematol [Internet]. 2026Apr.15 [cited 2026Apr.21];111(s2). Available from: https://haematologica.org/article/view/haematol.2026.s2.14042